Foreign strategic shareholders are now present in most of the leading pharmaceutical producers in Việt Nam, like DHG Pharmaceutical JSC, Domesco, Traphaco, Imexpharm, Hataphar, and Pymepharco, with some even holding more than 51 per cent or the whole of charter capital.Tokyo-based pharmaceutical company Taisho Pharmaceutical is the parent company holding the controlling interest of 51 per cent of shares in DHG Pharma.Abbott also successfully acquired a 52 per cent stake in Domesco through its subsidiary, CFR International Spa, while German pharmaceutical company STADA Group Arzneimittel purchased all shares of Pymepharco and delisted the company in 2021.SK Investment Vina III, the investment arm of SK Group, is the largest shareholder holding nearly 48 per cent of shares in Imexpharm. Calculating other related companies, the ownership rate of this group reaches over 55 per cent.Meanwhile, another South Korean pharmaceutical firm Daewoong Pharmaceutical and Japanese company ASKA Pharmaceutical are strategic shareholders of Traphaco and Hataphar, with ownership rates of 15 per cent and 25 per cent, respectively.These acquisitions, however, are not easy tasks. Some deals have lasted up to a year, with trillions of đồng spent.In 2012, Abbott purchased 8.2 million shares of Domesco and became its major shareholder holding 45.94 per cent. Then, after Domesco expanded the allowance of foreign ownership to 100 per cent in September 2016, Abbott did not miss the chance to raise its stake to 51.69 per cent.Abbott was estimated to have spent VNĐ400 billion (US$17 million) to acquire Domesco. The value of Domesco shares owned by Abbott is now nearly VNĐ1.1 trillion, more than twice the initial investment.Taisho began acquiring DHG Pharma in 2016 after pouring $100 million to buy 24.44 per cent of the firm's shares at the price of VNĐ100,000 a share, 20-30 per cent higher than the market priceGiven the large population size, the growth potential of the pharmaceutical industry in the med- and long-term is bright. The increase in per capita income also means people are spending more on healthcare products.By mid-2019, the Japanese giant raised their ownership to over 51 per cent, officially completing its acquisition of DHG Pharma.It's estimated that Taisho spent about VNĐ7 trillion on the deal, which is considered the largest M&A in the Vietnamese pharmaceutical industry to date.Three years after completing the acquisition, Taisho has seen steady profits from the investment as the market value of its holding shares reaches has reached close to VNĐ8.3 trillion.The presence of foreign strategic shareholders, with financial and technological strength, has helped domestic pharmaceutical enterprises significantly improve their competitive edge and expand into new markets.According to BMI, the industry's market size is currently around US$7.7 billion and could rise to US$16.1 billion by 2026. Fitch Solutions forecasts that the revenue of the country's pharmaceutical industry will grow steadily with an expected compound annual growth rate of about 6.72 per cent between 2022 and 2026 thanks to the rising demand for healthcare products.Last year, the IQVIA Institute ranked Việt Nam in the Pharmerging Market, the group of 17 countries with the highest growth in the pharmaceutical industry in the world. (ICE HO CHI MINH CITY)

Fonte notizia: Vietnam News